Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunome-derived vaccines.

Anne S De Groot

    Expert Opinion on Biological Therapy
    |June 4, 2004
    PubMed
    Summary
    This summary is machine-generated.

    Immune protection can be achieved by targeting a subset of pathogen antigens, not the entire genome. This principle, known as immunome-derived vaccines, is advancing vaccine development for infectious diseases and cancer.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Reduced T cell epitope cross-conservation and immunogenic potential is associated with emergence of a dominant influenza subclade K in 2025.

    Human vaccines & immunotherapeutics·2026
    Same author

    HLA Class II Alleles DRB1*11:01 and DQB1*03:01 Unmask Immunogenetic Susceptibility to Anti-Nivolumab Antibodies in Combination with Ipilimumab.

    The AAPS journal·2026
    Same author

    Immunogenicity risk assessment of peptide-related impurities identified in generic teriparatide products.

    Frontiers in immunology·2025
    Same author

    Establishment of Immune Biobank for Vaccine Immunogenicity Prediction Using In Vitro and In Silico Methods Against Porcine Reproductive and Respiratory Syndrome Virus.

    Vaccines·2025
    Same author

    A method for identifying neoantigens through isolation of circulating tumor cells using apheresis among patients with advanced-stage cancer.

    Frontiers in immunology·2025
    Same author

    T cell epitope content comparison using EpiCC correlates with vaccine efficacy against heterologous porcine reproductive and respiratory syndrome virus type 2 strains.

    Frontiers in microbiology·2025
    Same journal

    Biologic modulation of ineffective erythropoiesis in thalassemia: mechanisms, clinical practice, and future targets.

    Expert opinion on biological therapy·2026
    Same journal

    TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

    Expert opinion on biological therapy·2026
    Same journal

    Type 2 inflammation and biologics: a twenty-year journey.

    Expert opinion on biological therapy·2026
    Same journal

    Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.

    Expert opinion on biological therapy·2026
    Same journal

    Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

    Expert opinion on biological therapy·2026
    Same journal

    Biological drugs for the treatment of children with atopic dermatitis.

    Expert opinion on biological therapy·2026
    See all related articles

    Area of Science:

    • Immunology
    • Vaccinology
    • Bioinformatics

    Background:

    • Effective immunity often relies on a subset of antigens and epitopes, rather than recognition of every potential epitope from a pathogen's genome.
    • Subunit vaccines for pneumococcal and hepatitis demonstrate that targeting specific antigens can confer protection.
    • The concept of 'immunome-derived vaccines' posits that host immune system interaction with a specific subset of antigens (the immunome) is sufficient for protection.

    Discussion:

    • Cancer immunity is likely restricted to the tumor's immunome, though identifying these antigens is challenging.
    • Researchers employ bioinformatics, epitope mapping, microarrays, and high-throughput assays to identify immunome components.
    • These identified components are utilized in the development of novel vaccines.

    Key Insights:

    Related Experiment Videos

    • Immune response to a limited set of antigens can be sufficient for protection against pathogens and cancer.
    • The immunome, representing antigens that interact with the host immune system, is the focus for new vaccine strategies.
    • Advanced computational and immunological tools are accelerating the discovery of immunome targets.

    Outlook:

    • Immunome-derived vaccines represent a new era in vaccine development, with at least one in clinical trials.
    • Ongoing improvements in immunoinformatics and immunological assays will further enhance the discovery and application of immunome-derived vaccines.
    • This approach holds promise for developing more targeted and effective vaccines for infectious diseases and cancer.